My mother suffers from Alzheimer's disease. Today I published an article on the Alzheimer's Reading Room weblog about recent developments with GAMMAGARD. Baxter is moving to a phase three clinical trial that should prove interesting. If you are investing long term you might want to familiarize yourself with these recent developments. I'll leave it to you to decide the merits and the potential opportunity.
You can read the article by following this link.
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
No comments:
Post a Comment